Compare up to 4 stocks side by side, across all 7 of StockIQ's scoring categories.
| Category | ANVS Annovis Bio, Inc. | ABBV AbbVie |
|---|---|---|
| Price | $1.14 +3.6% | $263.96 -0.0% |
| StockIQ Score | 35F Weak Risk: High | 59C Moderate Risk: High |
| Technical | 6F | 85A |
| Fundamental | 42D | 57C |
| Growth | 52C- | 34F |
| Fair Value | 50C- | 33F |
| News | 50C- | 100A+ |
| Quality | — | 42D |
| Risk | 34F | 36F |
Scores are based on real financial data only and do not constitute investment advice. How the score is calculated
ABBV outperforms ANVS in investor (59 vs 35), technical (85 vs 6) and fundamental scores (57 vs 42). ANVS leads in growth (52 vs 34) and valuation (50 vs 33). The ratings reflect this, with ABBV rated MODERATE and ANVS rated WEAK.
